Thomas Reiser/X
Aug 19, 2025, 14:02
Thomas Reiser Invites Clinicians to Join ISTH Survey on APS Diagnosis and Antithrombotic Treatment in Acute Ischemic Cardiac Disease
Thomas Reiser, Executive Director of International Society on Thrombosis and Haemostasis (ISTH), shared a post on X:
“Your expertise is requested!
Take this survey from the ISTH SSC Subcom. on Lupus Anticoagulant/Antiphospholipid Antibodies on APS diagnosis and antithrombotic treatment in patients with acute ischemic cardiac disease to assess current clinical practices.”
Check for more information here.
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis